Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)

Inhibikase Therapeutics (IKT) has disclosed Notes Payables for 2 consecutive years, with $248911.0 as the latest value for Q4 2021.

  • Quarterly Notes Payables rose 485.2% to $248911.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $248911.0 through Dec 2021, up 485.2% year-over-year, with the annual reading at $248911.0 for FY2021, 485.2% up from the prior year.
  • Notes Payables for Q4 2021 was $248911.0 at Inhibikase Therapeutics, roughly flat from $248911.0 in the prior quarter.
  • The five-year high for Notes Payables was $994789.0 in Q1 2021, with the low at $42534.0 in Q4 2020.